443 related articles for article (PubMed ID: 26727596)
41. Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease.
Yamada A; Akimoto H; Kagawa S; Guillemin GJ; Takikawa O
J Neurochem; 2009 Aug; 110(3):791-800. PubMed ID: 19457071
[TBL] [Abstract][Full Text] [Related]
42. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
[TBL] [Abstract][Full Text] [Related]
43. Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase.
Ogawa K; Hara T; Shimizu M; Ninomiya S; Nagano J; Sakai H; Hoshi M; Ito H; Tsurumi H; Saito K; Seishima M; Tanaka T; Moriwaki H
Cancer Sci; 2012 May; 103(5):951-8. PubMed ID: 22320717
[TBL] [Abstract][Full Text] [Related]
44. FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.
Kobayashi N; Kubota K; Kato S; Watanabe S; Shimamura T; Kirikoshi H; Saito S; Ueda M; Endo I; Inayama Y; Maeda S; Nakajima A
Pancreatology; 2010; 10(5):631-40. PubMed ID: 21051918
[TBL] [Abstract][Full Text] [Related]
45. Immuno-regulatory function of indoleamine 2,3 dioxygenase through modulation of innate immune responses.
Poormasjedi-Meibod MS; Jalili RB; Hosseini-Tabatabaei A; Hartwell R; Ghahary A
PLoS One; 2013; 8(8):e71044. PubMed ID: 23940687
[TBL] [Abstract][Full Text] [Related]
46. The kynurenine system and immunoregulation.
Mándi Y; Vécsei L
J Neural Transm (Vienna); 2012 Feb; 119(2):197-209. PubMed ID: 21744051
[TBL] [Abstract][Full Text] [Related]
47. Proapoptotic activity of indoleamine 2,3-dioxygenase expressed in renal tubular epithelial cells.
Mohib K; Guan Q; Diao H; Du C; Jevnikar AM
Am J Physiol Renal Physiol; 2007 Sep; 293(3):F801-12. PubMed ID: 17609291
[TBL] [Abstract][Full Text] [Related]
48. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice.
Lin H; Yan J; Wang Z; Hua F; Yu J; Sun W; Li K; Liu H; Yang H; Lv Q; Xue J; Hu ZW
Hepatology; 2013 Jan; 57(1):171-82. PubMed ID: 22859216
[TBL] [Abstract][Full Text] [Related]
49. Indoleamine 2,3-dioxygenase-1, a Novel Therapeutic Target for Post-Vascular Injury Thrombosis in CKD.
Walker JA; Richards S; Whelan SA; Yoo SB; Russell TL; Arinze N; Lotfollahzadeh S; Napoleon MA; Belghasem M; Lee N; Dember LM; Ravid K; Chitalia VC
J Am Soc Nephrol; 2021 Nov; 32(11):2834-2850. PubMed ID: 34716244
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of antigen-specific immune responses by co-application of an indoleamine 2,3-dioxygenase (IDO)-encoding vector requires antigen transgene expression focused on dendritic cells.
Sudowe S; Höhn Y; Renzing A; Maxeiner J; Montermann E; Habermeier A; Closs E; Bros M; Reske-Kunz AB
Amino Acids; 2020 Mar; 52(3):411-424. PubMed ID: 32008091
[TBL] [Abstract][Full Text] [Related]
51. Neuronal localization of indoleamine 2,3-dioxygenase in mice.
Roy EJ; Takikawa O; Kranz DM; Brown AR; Thomas DL
Neurosci Lett; 2005 Oct; 387(2):95-9. PubMed ID: 16076525
[TBL] [Abstract][Full Text] [Related]
52. Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in lecithin:retinol acyltransferase-deficient mice primarily through retinoid actions immediately after carcinogen administration.
Shirakami Y; Gottesman ME; Blaner WS
Carcinogenesis; 2012 Feb; 33(2):268-74. PubMed ID: 22116467
[TBL] [Abstract][Full Text] [Related]
53. Sodium butyrate inhibits interferon-gamma induced indoleamine 2,3-dioxygenase expression via STAT1 in nasopharyngeal carcinoma cells.
He YW; Wang HS; Zeng J; Fang X; Chen HY; Du J; Yang XY
Life Sci; 2013 Oct; 93(15):509-15. PubMed ID: 23942267
[TBL] [Abstract][Full Text] [Related]
54. Immune cell proliferation is suppressed by the interferon-gamma-induced indoleamine 2,3-dioxygenase expression of fibroblasts populated in collagen gel (FPCG).
Sarkhosh K; Tredget EE; Karami A; Uludag H; Iwashina T; Kilani RT; Ghahary A
J Cell Biochem; 2003 Sep; 90(1):206-17. PubMed ID: 12938169
[TBL] [Abstract][Full Text] [Related]
55. Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO.
Zhang A; Zheng Y; Que Z; Zhang L; Lin S; Le V; Liu J; Tian J
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1883-90. PubMed ID: 24980548
[TBL] [Abstract][Full Text] [Related]
56. Haemophilus ducreyi lipooligosaccharides induce expression of the immunosuppressive enzyme indoleamine 2,3-dioxygenase via type I interferons and tumor necrosis factor alpha in human dendritic cells.
Li W; Katz BP; Spinola SM
Infect Immun; 2011 Aug; 79(8):3338-47. PubMed ID: 21576329
[TBL] [Abstract][Full Text] [Related]
57. Abberent expression of NOR1 protein in tumor associated macrophages contributes to the development of DEN-induced hepatocellular carcinoma.
Chen S; Zheng P; Wang W; Yi M; Chen P; Cai J; Li J; Peng Q; Ban Y; Zhou Y; Zeng Z; Li X; Xiong W; Li G; Xiang B
J Cell Physiol; 2018 Jun; 233(6):5002-5013. PubMed ID: 29227538
[TBL] [Abstract][Full Text] [Related]
58. Interleukin-17A Plays a Pivotal Role in Chemically Induced Hepatocellular Carcinoma in Mice.
Sun C; Kono H; Furuya S; Hara M; Hirayama K; Akazawa Y; Nakata Y; Fujii H
Dig Dis Sci; 2016 Feb; 61(2):474-88. PubMed ID: 26467699
[TBL] [Abstract][Full Text] [Related]
59. Alpha-galactosylceramide modulates the induction of indoleamine 2,3-dioxygenase in antigen presenting cells.
Fallarini S; Paoletti T; Panza L; Lombardi G
Biochem Pharmacol; 2008 Sep; 76(6):738-50. PubMed ID: 18671950
[TBL] [Abstract][Full Text] [Related]
60. Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development.
Rutella S; Bonanno G; De Cristofaro R
Endocr Metab Immune Disord Drug Targets; 2009 Jun; 9(2):151-77. PubMed ID: 19519465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
